NYSE
$70.17▼ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $35.06BShares out 500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
1- 8.10After-hours26.08.11 05:316-KKey event#●●●#●●●
ALCON INCBullish
알콘(Alcon)은 2026년 2분기 매출 28억 달러를 기록하며 전년 동기 대비 8% 성장했으나, 파워비전(PowerVision) 프로그램 중단에 따른 4억 200만 달러의 비현금성 손상차손 반영으로 분기 순이익은 0달러를 기록했습니다. 다만, 핵심 희석 주당순이익(Core EPS)은 0.84달러로 전년 대비 11% 증가했으며, 회사는 견조한 실적을 바탕으로 2026년 연간 핵심 영업이익률 및 EPS 성장 가이던스를 상향 조정했습니다.…more
$70.17-0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
News
GlobeNewswire- 3d agoRegular26.10.21 22:33Bullish#●●●#●●●#●●●
Algoma Central Increases Convertible Debenture Offering
Algoma Central has increased the size of its 6.20% convertible unsecured subordinated debenture offering due to strong market demand. The proceeds will be used to fund newbuild investments, mergers and acquisitions, and general corporate purposes.…more
$70.17-0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoAfter-hours26.10.21 05:36
●●●●●●●● ●●●●● ●●●●●●
Alcon has acquired Neurotech Pharmaceuticals for $550 million to expand its retina portfolio with the FDA-approved treatment ENCELTO. This acquisition provides Alcon with a unique therapy for Macular Telangiectasia Type 2, a rare condition with previously limited treatment options.…more
$70.17-0.06%vs prev closeShareBenzinga - 4d agoAfter-hours26.10.21 05:31
●●●●●●●● ●●●●● ●●●●●●
Algoma Central is raising $62.5 million through convertible debentures to fund new vessel investments and potential acquisitions. Investors should be aware that the conversion of these debentures into common shares could lead to equity dilution.…more
$70.17-0.06%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report